New data showed LIVALO® (pitavastatin) met primary endpoint of LDL-C reduction when compared with pravastatin
31 May 2012 | By Eli Lilly and Company
Results of the PREVAIL U.S. study...
List view / Grid view
31 May 2012 | By Eli Lilly and Company
Results of the PREVAIL U.S. study...
31 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim is establishing a new 50 million-plus euro pilot plant facility...
30 May 2012 | By GlaxoSmithKline
GlaxoSmithKline has submitted regulatory applications in the European Union and US...
30 May 2012 | By Eli Lilly and Company
Eli Lilly & Company opened the LCRDC...
30 May 2012 | By Biogen Idec
Biogen Idec will join with the MS community around the world...
30 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Taizhou China Medical City announced the signing of an agreement...
29 May 2012 | By GlaxoSmithKline
GSK which has the marketing rights for Lovaza in the US and Puerto Rico...
29 May 2012 | By GlaxoSmithKline
GlaxoSmithKline plc. announced the start of a Phase III programme...
29 May 2012 | By H. Lundbeck A/S
The pivotal clinical programme is in planning...
29 May 2012 | By Abbott
Latest investigational research findings on HUMIRA®...
28 May 2012 | By Sanofi
The group pledges continuous commitment to diabetes management in China...
25 May 2012 | By Pfizer
The CHMP of the EMA has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU)...
25 May 2012 | By Novo Nordisk
Novo Nordisk receives a positive opinion on recombinant factor XIII product (rFXIII)...
25 May 2012 | By Merck
Merck welcomes the launch of Africa’s first national rotavirus vaccination program...
25 May 2012 | By GlaxoSmithKline
Positive opinion recommending marketing authorisation for Votrient®...